Table 1.
Patient, tumor, and treatment characteristics
| Variable | No. (%) (n=1,382) |
|---|---|
| Age, median (range, yr) | 48 (24-85) |
| Menopausal status | |
| Premenopausal | 841 (60.9) |
| Postmenopausal | 530 (38.4) |
| Unknown | 11 (0.8) |
| T stage | |
| T1 | 562 (40.7) |
| T2 | 820 (59.3) |
| Tumor histologic grade | |
| Low-intermediate | 807 (58.4) |
| High | 547 (39.6) |
| Unknown | 28 (2.0) |
| Resection margin | |
| Negative (≥ 2 mm) | 1,193 (86.3) |
| Close (< 2 mm) | 189 (13.7) |
| No. of nodes examined | |
| Median | 15 (1-64) |
| < 10 | 275 (19.9) |
| ≥ 10 | 1,107 (80.1) |
| No. of positive nodes | |
| 1 | 813 (58.8) |
| 2 | 371 (26.8) |
| 3 | 198 (14.3) |
| Hormonal receptor | |
| Positive | 1,022 (74.0) |
| Negative | 360 (26.0) |
| HER2 amplification | |
| Positive | 407 (29.5) |
| Negative | 917 (66.4) |
| Unknown | 58 (4.2) |
| Systemic treatment | |
| Endocrine therapy alone | 41 (3.0) |
| Chemotherapy alone | 328 (23.7) |
| Both | 1,005 (72.7) |
| Neither | 8 (0.6) |
| Chemotherapy | |
| Taxane-containing | 1,104 (79.9) |
| Non-taxane containing | 229 (16.6) |
| Not done | 49 (3.5) |
| Trastuzumab | |
| HER2+ and trastuzumab– | 154 (11.1) |
| HER2+ and trastuzumab+ | 253 (18.3) |
| Biological subtype | |
| Luminal A | 554 (40.1) |
| Luminal B | 187 (13.5) |
| Luminal HER2 | 209 (15.1) |
| HER2+ | 198 (14.3) |
| Triple negative | 157 (11.4) |
| Unknown | 77 (5.6) |
HER2, human epidermal growth factor receptor 2.